Innovation Pharmaceuticals Inc (IPIX)

[BonelessCat]

There are about 30 articles published on Pemetrexed development (Alimta) at Eli Lilly. Menon was the toxicologist and pharmacoligist in recombining pemetrexed with buffers and other compounds that became Alimta.

Here are two from PubMed:

1. Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts.

Teicher BA, Chen V, Shih C, Menon K, Forler PA, Phares VG, Amsrud T.

Clin Cancer Res. 2000 Mar;6(3):1016-23.


2. MTA (LY231514) in combination treatment regimens using human tumor xenografts and the EMT-6 murine mammary carcinoma.

Teicher BA, Alvarez E, Liu P, Lu K, Menon K, Dempsey J, Schultz RM.

Semin Oncol. 1999 Apr;26(2 Suppl 6):55-62.